Abstract
Cytarabine ocfosfate (SPAC) was administered orally to 19 patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SPAC was administered at doses of 200-300 mg/day for more than 14 days with granulocyte colony-stimulating factor (G-CSF). Four of the 12 patients with AML and 1 of the 7 patients with MDS achieved complete remission (CR) after one cycle of SPAC treatment. Especially, 3 of the 6 patients with newly diagnosed AML achieved CR. Major side effects of SPAC were myelosuppression and tolerable gastrointestinal disorders. The treatment with SPAC is a therapeutic option in elderly patients or patients with organ failure.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage*
-
Arabinonucleotides / administration & dosage*
-
Cytidine Monophosphate / administration & dosage
-
Cytidine Monophosphate / analogs & derivatives*
-
Drug Therapy, Combination
-
Female
-
Granulocyte Colony-Stimulating Factor / administration & dosage*
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy*
Substances
-
Antineoplastic Agents
-
Arabinonucleotides
-
Granulocyte Colony-Stimulating Factor
-
1-arabinofuranosylcytosine-5'-stearylphosphate
-
Cytidine Monophosphate